Skip to main
ALMS
ALMS logo

Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis Inc (ALMS) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alumis Inc presents a strong outlook due to its innovative approach in developing targeted therapies for autoimmune disorders, which is expected to significantly improve patient outcomes compared to traditional broad immunosuppression. The projected peak sales of $2 billion for its SLE product highlight the potential market impact, even when considering a conservative approval probability of only 20%. Additionally, the ongoing development of ESK-001 for psoriatic arthritis, supported by positive data from comparable therapies, further underscores the company’s potential for revenue growth in the autoimmune treatment space.

Bears say

The financial outlook for Alumis Inc is negatively impacted by several significant risks associated with its lead candidate ESK-001, including potential delays in advancing pivotal trials and demonstrating compelling efficacy for conditions such as psoriasis and systemic lupus erythematosus. Additionally, the company faces challenges in completing regulatory submissions and securing necessary approvals in key markets, which could hinder its ability to capitalize on market opportunities. The presence of broad competitive pressures in the immunology and inflammation sector, coupled with risks of slower-than-anticipated market uptake and possible dilution, further exacerbates the negative sentiment around the stock.

Alumis Inc (ALMS) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alumis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alumis Inc (ALMS) Forecast

Analysts have given Alumis Inc (ALMS) a Buy based on their latest research and market trends.

According to 6 analysts, Alumis Inc (ALMS) has a Buy consensus rating as of Oct 8, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alumis Inc (ALMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.